84 related articles for article (PubMed ID: 27845109)
1. Re: Single-Nucleotide Polymorphism in the 5-α-Reductase Gene (SRD5A2) is Associated with Increased Prevalence of Metabolic Syndrome in Chemotherapy-Treated Testicular Cancer Survivors.
Richie JP
J Urol; 2016 Dec; 196(6):1677-1678. PubMed ID: 27845109
[No Abstract] [Full Text] [Related]
2. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
3. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic variants in the two isoforms of 5α-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome.
Graupp M; Wehr E; Schweighofer N; Pieber TR; Obermayer-Pietsch B
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):175-9. PubMed ID: 21530059
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of 17 β-hydroxysteroid dehydrogenase 3 and the risk of hypospadias.
Sata F; Kurahashi N; Ban S; Moriya K; Tanaka KD; Ishizuka M; Nakao H; Yahata Y; Imai H; Kakizaki H; Nonomura K; Kishi R
J Sex Med; 2010 Aug; 7(8):2729-38. PubMed ID: 20059664
[TBL] [Abstract][Full Text] [Related]
8. Analysis of polymorphisms in the SRD5A2 gene and semen parameters in Estonian men.
Peters M; Saare M; Kaart T; Haller-Kikkatalo K; Lend AK; Punab M; Metspalu A; Salumets A
J Androl; 2010; 31(4):372-8. PubMed ID: 19926884
[TBL] [Abstract][Full Text] [Related]
9. SRD5A2 gene polymorphisms affect the risk of breast cancer.
Francis A; Sarkar S; Pooja S; Surekha D; Rao DR; Rao L; Ramachandra L; Vishnupriya S; Satyamoorthy K; Thangaraj K; Rajender S
Breast; 2014 Apr; 23(2):137-41. PubMed ID: 24365257
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
11. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
[TBL] [Abstract][Full Text] [Related]
12. SRD5A2 gene mutations--a population-based review.
Samtani R; Bajpai M; Ghosh PK; Saraswathy KN
Pediatr Endocrinol Rev; 2010 Sep; 8(1):34-40. PubMed ID: 21037542
[TBL] [Abstract][Full Text] [Related]
13. Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2).
Davis DL; Russell DW
Hum Mol Genet; 1993 Jun; 2(6):820. PubMed ID: 8353504
[No Abstract] [Full Text] [Related]
14. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
15. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
16. Novel nucleotide insertions in two unrelated Indian patients with 5α reductase 2 deficiency leading to premature termination of SRD5A2 enzyme.
Shabir I; Khurana ML; Marumudi E; Khadgawat R; Ammini AC
Steroids; 2013 Dec; 78(12-13):1159-63. PubMed ID: 24012728
[TBL] [Abstract][Full Text] [Related]
17. Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population.
Rahimi M; Ghanbari M; Fazeli Z; Rouzrokh M; Omrani S; Mirfakhraie R; Omrani MD
J Endocrinol Invest; 2017 Apr; 40(4):391-396. PubMed ID: 27848231
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of the SRD5A2 in 46,XY subjects with incomplete virilization: the P212R substitution of the steroid 5alpha-reductase 2 may constitute an ancestral founder mutation in Mexican patients.
Vilchis F; Ramos L; Méndez JP; Benavides S; Canto P; Chávez B
J Androl; 2010; 31(4):358-64. PubMed ID: 20019388
[TBL] [Abstract][Full Text] [Related]
19. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Tong M; Jin YY; Li G; Liu SM; Ji CD
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
[TBL] [Abstract][Full Text] [Related]
20. Homozygous Ala65Pro Mutation with V89L Polymorphism in SRD5A2 Deficiency.
Eren E; Edgünlü T; Asut E; Karakaş Çelik S
J Clin Res Pediatr Endocrinol; 2016 Jun; 8(2):218-23. PubMed ID: 26761946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
